Clinically validated in two clinical studies on independent cohorts and CE IVD marked, it offers remarkable performance with sensitivity and specificity above 80%. Its objective is to help practitioners make a quicker diagnosis; reducing the diagnostic delay to a few days; patient care being consequently dramatically improved and patient management optimized.
“When the brain malfunctions, it sends signals just as a sick liver would. These signals, or biomarkers, can then be captured by a blood test, based on RNA editing, allowing for a faster diagnosis. The introduction of biology into psychiatry is a revolution”, comments Dr. Dinah Weissmann, co-founder and Scientific Director of ALCEDIAG.
“We are very proud to be part of the EDIT-B project, which will give an answer to so many patients who must face such a difficult patient journey before being diagnosed. The availability of this test will really be a game-changer in the psychiatric area”, states Giovanni Gianolli, CEO of SYNLAB Italy.
EDIT-B™ complements the existing clinical scales. Technically, it measures the RNA editing of specific markers in patients’ blood. ALCEDIAG which developed the test and ensured its regulatory compliance, uses state-of-the-art Next Generation Sequencing (NGS) technology coupled with proprietary algorithms using artificial intelligence (AI).
EDIT-B™ is now available in Italy. It will be soon available in France and Switzerland during 2023 and gradually in other countries (SYNLAB is present 26 countries in Europe).